Organizational aspects of Global Therapy

In order to improve therapy, to design the best drugs is of course helpful. But!: Imagine an elder patient who developed a breast cancer still without metastases. e sanitary system takes weeks to follow the standard protocol. e patient is rst suggested hormone therapy. Unfortunately, she is unresponsive. e oncologic decision is then to undergo surgery, that would be quite resolutive, at least for the next few years, unless the patient die under it, which would be sad, but probably not the worst scenario. In the meanwhile, of such a month of protocol, the patient develops lymphatic rst involvement. At this point, surgery will still probably used, but it will not be resolutive, thus further implying a chemotherapy follow up, for the joy of pharma companies and maybe of physicians, and the suffering of the patients and her relatives.